SBIR/STTR Research Award
mRNA-Directed Differentiation of hPSC to A10 Dopaminergic Neurons
Award amount
$225,000Program and phase
SBIR · Phase IAward year
2016Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- MOLECULAR TRANSFER, INC.
- Proposal award date
- 2016-08-01
- Contract end date
- 2017-07-31
- UEI
- Not reported
- Solicitation number
- PA15-269
- Topic code
- NIDA
Research abstract
SUMMARY ABSTRACT
Drug addiction is a complex disease There are a variety of potential neural systems and circuits
involved some of which are physiologically or epigenetically altered through addiction Drug abuse and
addiction weigh heavily on the U S through health and crime related costs as well as broader societal
issues related to safety family education and employment In order to fully understand the
physiological changes in the addicted brain on a cellular level we must have the proper tools for study
The first step toward creating these tools is the establishment of an in vitro system of human
dopaminergic neurons Such a system would not only enable cellular molecular and physiological
studies into the mechanisms of addiction but also open the door to the screening and development of
small molecules and drugs that can potentially block the onset of changes associated with addiction or
even reverse these changes
Human pluripotent stem cells hPSC can be differentiated into populations of neurons enriched
for dopaminergic neurons However current protocols yield low percentages of dopaminergic neurons
and are not robust and reproducible Additionally most of the stem cell to dopaminergic neuron
research is focused on Parkinsonandapos s Disease and very little effort has been dedicated to deriving the
specific type of dopaminergic neurons implicated in addiction
Transfection of synthetic mRNA into cells is technology to fine tune gene expression This
technology has been used to reprogram adult somatic cells to pluripotent stem cells and to
transdifferentiate adult somatic cells to neurons and other cell types We propose to develop novel
reagents and protocols for mRNA mediated directed differentiation of hPSC to dopaminergic neurons
relevant for addiction research This project will yield novel cell specific high efficiency mRNA
transfection reagents and protocols It will result in a detailed work flow for the directed differentiation
of A dopaminergic neurons from undifferentiated human iPSC And finally it will produce a platform
system for the study of mechanisms of drug abuse at the cellular and molecular level while allowing
screening assays to be performed on this system A realistic future application of this platform Phase II
is the creation of iPSC from cells taken from addicted individuals carrying identified genetic variants
identified to be risk factors for addictive behavior These patient specific iPSC can then be differentiated
to A DA neurons and studied for possible insights into how these genetic variations affect the
development of addictive behavior among other things
PROJECT NARRATIVE
Drug abuse and addiction weigh heavily on the U S through health and crime related costs as well as
broader societal issues related to safety family education and employment In order to fully understand
the physiological changes in the addicted brain on a cellular level we must have the proper tools for
study In this application we propose to develop tools to study addiction directly at the cellular and
molecular levels
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Wearable Wireless Respiratory Monitoring System that Detects and Predicts Opioid Induced Respiratory Depression
- Building and testing the Life Enhancement and Advocacy Programming digital training tool (LEAPLink) to better serve people with lived experience of homelessness and substance use disorder
- A digital intervention to decrease self-stigma among pregnant and postpartum women with opioid use disorder
- Development of medication for the treatment of respiratory depression due to opioid (prescribed or illicit) overdose/multidrug (polysubstance) overdose in a hospital or community setting.
- Creation and Validation of the Dose-Opioid-Source Evaluation tool (DOSE) - a Robust Opioid Use Clinical Outcome Assessment for Qualification as an FDA Medical Device Development Tool (MDDT)